Dendreon, JAZZ and Regeneron Among Best Stock Price Performers

Once again, Dendreon was a top percentage gainer among the major universe of stocks today. Here are the other 4 companies, along with Dendreon, rounding out the stock market’s major price percentage gainers on Wall Street today:

Big gainers:

Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ): Jazz closed at $45.39, up $3.93, or 9.48 percent. Their 52-week trading range has been $18.85 to $47.88. Jazz Pharmaceuticals doubled its after hour gain yesterday after revising 2012 revenue guidance upward. Muzho upped their price target from $52 to $62.

Dendreon Corporation (NASDAQ:DNDN): Dendreon closed at $12.35, up $1.73, or 16.29 percent. Their 52-week trading range has been $6.46 to $43.96.

VirnetX Holding Corporation (NYSEAMEX:VHC): VirnetX closed at $26.73, up $2.01, or 8.13 percent. Their 52-week trading range has been$11.02 to $41.77. VirnetX moved up 2 percent in premarket after positive remarks from Cowen. VirnetX has requested to reexamine a key patent, and the firm thinks the U.S. Patent and Trademark Office’s move favors VirnetX’s position.  The firm thinks VirnetX’s claims will hold up and shares will double this year.

Magna International Inc. (NYSE:MGA): Magna closed at $36.22, up $2.15, or 6.31 percent. Their 52-week trading range has been $30.03 to $62.20.  In cooperation with a Department of Justice antitrust probe concerning the automobile tool industry, Magna says it will turn over documents related to bids made by its Cosma International unit as a Tier 1 supplier.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Regeneron closed at $65.79, up $4.85, or 7.96 percent. Their 52-week trading range has been$20.45 to $71.74. Regeneron perks up after Jefferies upgrades from Hold to Buy. Analysts cite increased demand for Regeneron’s Eylea drug and further distribution through Express Scripts.

 Featured Reading: Gold (NYSEARCA:GLD) and Silver (NYSEARCA:SLV) Hold Steady: American Eagle Sales Soar>>

To contact the reporter on this story: Jim Wilkerson at

To contact the editor responsible for this story: Damien Hoffman at